4.6 Article

The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction

期刊

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
卷 28, 期 8, 页码 897-904

出版社

OXFORD UNIV PRESS
DOI: 10.1177/2047487319896648

关键词

Icosapent ethyl; 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors; cost-effectiveness; cardiovascular disease; Australia

向作者/读者索取更多资源

The study aimed to assess the cost-effectiveness of icosapent ethyl in combination with statin therapy for the prevention of cardiovascular disease in the Australian public healthcare system. Results suggest that the combination therapy may be cost-effective, especially in the secondary preventive setting.
Aims The aim of this study was to estimate the cost-effectiveness, from the perspective of the Australian public healthcare system, of icosapent ethyl in combination with statin therapy compared with statin alone for the prevention of cardiovascular disease. Methods and results A Markov model populated with data from the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial was designed to predict the effectiveness and costs of icosapent ethyl in combination with statins compared with statins alone over a 20-year time horizon. Data inputs for costs and utilities were sourced from published sources. The annual costs of icosapent ethyl were assumed to be AUD1637 (USD2907) per person. All future costs and outcomes were discounted annually by 5%. The main outcome of interest was incremental cost-effectiveness ratios in terms of cost per quality adjusted life year (QALY) gained and per year of life saved (YoLS). Over a 20-year time horizon, compared with statin alone, icosapent ethyl in combination with statin was estimated to cost an additional AUD$13,022 per person, but led to 0.338 YoLS and 0.289 QALYs gained (all discounted). These equated to incremental cost-effectiveness ratios of AUD45,036 per QALY gained and AUD38,480 per YoLS. Sub-analyses for primary and secondary prevention were AUD96,136 and AUD35,935 per QALY gained, respectively. The results were sensitive to time-horizon, age related trends and the acquisition price of icosapent ethyl. Conclusion Compared with statin alone, icosapent ethyl in combination with statin therapy is likely to be cost-effective in the prevention of cardiovascular disease assuming a willingness-to-pay threshold of AUD50,000 per QALY gained, especially in the secondary preventive setting.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Endocrinology & Metabolism

Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis

Richard Ofori-Asenso, Berhe W. Sahle, Ken Lee Chin, Mohsen Mazidi, Zanfina Ademi, Marie Louise De Bruin, Danny Liew

Summary: The study found that real-world adherence and persistence to SGLT2 inhibitors is poor, with approximately 60% of patients adherent at six months and 50% at one year, while persistence data showed even lower proportions. Targets for improving treatment adherence and persistence need to be identified and appropriate interventions implemented.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2021)

Article Cardiac & Cardiovascular Systems

Clinical Outcomes in Older Patients Undergoing Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndromes

Michael Lim, Diem T. Dinh, Angela Brennan, Danny Liew, Christopher Reid, Jeffrey Lefkovits, Stephen J. Duffy, Nick Andrianopoulos, Dion Stub

Summary: This study investigated contemporary outcomes of older patients with NSTEACS undergoing PCI and found that those with left ventricular systolic dysfunction or renal impairment are at increased risk of MACCE post PCI. Randomised studies are needed to determine if invasive management remains beneficial for these patients compared with medical therapy.

HEART LUNG AND CIRCULATION (2021)

Article Cardiac & Cardiovascular Systems

Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective

Feby Savira, Bing H. Wang, Andrew R. Kompa, Zanfina Ademi, Alice J. Owen, Sophia Zoungas, Andrew Tonkin, Danny Liew, Ella Zomer

Summary: The study found that adding dapagliflozin as an adjunct therapy to standard care for patients with chronic heart failure and reduced ejection fraction can prevent acute heart failure hospitalizations, increase years of life and quality-adjusted life-years, at a cost-effective ratio well below the Australian willingness-to-pay threshold.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)

Article Cardiac & Cardiovascular Systems

Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029

Clara Marquina, Stella Talic, Sandra Vargas-Torres, Marjana Petrova, Dina Abushanab, Alice Owen, Sean Lybrand, David Thomson, Danny Liew, Ella Zomer, Zanfina Ademi

Summary: The study estimated the health and economic burden of cardiovascular disease in Australia from 2020 to 2029, finding a significant impact in terms of morbidity, mortality, healthcare costs, and productivity losses. The model projected a high number of fatal and non-fatal cardiovascular events, with a substantial number of Australians expected to have prevalent cardiovascular disease by 2029. The total cost of cardiovascular disease, including healthcare costs and productivity losses, was projected to exceed a significant amount in Australian dollars.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Review Cardiac & Cardiovascular Systems

First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis

Dina Abushanab, Daoud Al-Badriyeh, Danny Liew, Zanfina Ademi

Summary: This study evaluated the cost-effectiveness of first-line empagliflozin plus standard care for patients with newly diagnosed type 2 diabetes and existing cardiovascular disease. The results indicate that adding empagliflozin to standard care can provide additional years of life and quality-adjusted life years for patients at a reasonable cost.

CURRENT PROBLEMS IN CARDIOLOGY (2022)

Article Cardiac & Cardiovascular Systems

Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients With Severe Aortic Stenosis

Jennifer Y. Zhou, Danny Liew, Stephen J. Duffy, Antony Walton, Nay Htun, Dion Stub

Summary: Recent studies suggest that balloon-expandable and self-expanding TAVI may offer cost-effective options compared to SAVR for low-risk patients with severe aortic stenosis. While balloon-expandable TAVI showed higher quality-adjusted survival years but higher costs, self-expanding TAVI was found to be economically dominant with lower costs and slightly lower increase in quality-adjusted survival years.

HEART LUNG AND CIRCULATION (2021)

Article Biochemistry & Molecular Biology

Attenuating PI3K/Akt- mTOR pathway reduces dihydrosphingosine 1 phosphate mediated collagen synthesis and hypertrophy in primary cardiac cells

Ruth R. Magaye, Feby Savira, Yue Hua, Xin Xiong, Li Huang, Christopher Reid, Bernard L. Flynn, David Kaye, Danny Liew, Bing H. Wang

Summary: Our study reveals a relationship between the PI3K/Akt-mTOR signaling cascade and collagen synthesis and myocyte hypertrophy induced by exogenous dhS1P in primary neonatal cardiac cells. In addition, PI3K inhibition also affects the gene expression related to S1P receptors and enzymes.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2021)

Article Endocrinology & Metabolism

Projecting the Incidence of Type 2 Diabetes-Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment

Jedidiah I. Morton, Stephen P. McDonald, Agus Salim, Danny Liew, Jonathan E. Shaw, Dianna J. Magliano

Summary: The study projected an increase in the incidence of ESKD-D over the coming decades, but widespread use of SGLT2is may help limit this increase. Diabetes prevention will be crucial in preventing the ever-increasing burden of diabetes complications.

DIABETES CARE (2021)

Article Economics

The Health and Productivity Burden of Depression in South Korea

Ella Zomer, YongJoo Rhee, Danny Liew, Zanfina Ademi

Summary: Major depression in South Korea affects over 500,000 individuals aged 15-54, leading to significant premature deaths, years of life lost, and productivity-adjusted life-years lost. The total economic impact of depression in terms of lost GDP is substantial, highlighting the need for improved prevention and treatment strategies to enhance long-term economic gains.

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2021)

Article Cardiac & Cardiovascular Systems

Quality of life and associations with health-related behaviours among older adults with increased cardiovascular risk

Thara Govindaraju, Tracy A. McCaffrey, John J. McNeil, Christopher M. Reid, Ben J. Smith, Duncan J. Campbell, Danny Liew, Alice J. Owen

Summary: This cross-sectional study examined the association between cardiovascular disease risk factors and quality of life in older adults. The study found that smoking was negatively associated with mental component score of quality of life, while physical activity was positively associated with mental component score. Alcohol consumption was positively associated with physical component score, and saturated fat intake showed a negative association with the physical functioning domain of quality of life.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2022)

Review Oncology

Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis

Abdallah Y. Naser, Richard Ofori-Asenso, Safaa Al Awawdeh, Sami Qadus, Hassan Alwafi, Danny Liew

Summary: In this study, a systematic review and meta-analysis were conducted to summarize the adherence and persistence rate among patients prescribed oral therapy for multiple myeloma. The analysis suggested that about 68% of patients were adherent and 36% discontinued treatment. These findings emphasize the need for interventions to improve treatment adherence in order to achieve desired clinical outcomes.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Review Cardiac & Cardiovascular Systems

Does Down syndrome influence the outcomes of congenital cardiac surgery? A systematic review and meta-analysis

Benjamen Wang, Justin Verrocchi, Danny Liew, Dominica Zentner

Summary: This study aims to compare the long-term outcomes after cardiac surgery in adults with and without Down syndrome (DS). The meta-analysis showed that DS does not affect long-term survival after congenital cardiac surgery in adulthood, but individuals with DS have a lower risk of cardiac reoperation. The study is limited by limited sample sizes and clinical heterogeneity.

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2023)

Article Endocrinology & Metabolism

Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis

Jedidiah Morton, Clara Marquina, Jonathan E. Shaw, Danny Liew, Kevan R. Polkinghorne, Zanfina Ademi, Dianna J. Magliano

Summary: The use of SGLT2i is cost-effective based on cardiovascular and kidney benefits for people with type 2 diabetes, while the use of GLP-1 RA is not.

DIABETOLOGIA (2023)

Article Endocrinology & Metabolism

The Cost of Control: Cost- effectiveness Analysis of Hybrid Closed-Loop Therapy in Youth

Anthony Pease, Emily Callander, Ella Zomer, Mary B. Abraham, Elizabeth A. Davis, Timothy W. Jones, Danny Liew, Sophia Zoungas

Summary: The study found that HCL therapy was more cost-effective than current care for young people with type 1 diabetes in Australia. The incremental cost-effectiveness ratio was AUD $32,789 per QALY gained, with the majority of simulations falling below the willingness-to-pay threshold of AUD $50,000 per QALY gained. Sensitivity analyses indicated that the results were robust.

DIABETES CARE (2022)

Article Health Care Sciences & Services

Do family meetings for hospitalised palliative care patients improve outcomes and reduce health care costs? A cluster randomised trial

Peter Hudson, Afaf Girgis, Kristina Thomas, Jennifer Philip, David C. Currow, Geoffrey Mitchell, Deborah Parker, Danny Liew, Caroline Brand, Brian Le, Juli Moran

Summary: Family meetings can help reduce psychological distress and enhance preparedness of family caregivers for their role. The study results suggest that these meetings may be conducted without increasing hospital health utilization impacts. Further health economic examination is recommended to fully understand the cost-benefit implications.

PALLIATIVE MEDICINE (2021)

暂无数据